Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT04345367) enrolled 727 adults with atopic dermatitis (eczema) — 362 in the abrocitinib group (a once-daily tablet) and 365 in the dupilumab group (an injection given every two weeks). The study was measuring two main things at early timepoints: how quickly each treatment reduced itch (scored on a 0–10 scale, where higher means worse), and how many participants saw a 90% or greater improvement in the overall area and severity of their eczema by week 4. The reported data shows that for the primary outcomes, 48.2% of participants in the abrocitinib group and 25.5% in the dupilumab group reported at least a 4-point drop in their worst itch score by week 2. For eczema area and severity, 28.5% of the abrocitinib group and 14.6% of the dupilumab group reached a 90% or greater improvement by week 4. As the study continued, the reported data shows the gap between the two groups appeared to narrow over time: by week 26, 54.6% of the abrocitinib group and 47.6% of the dupilumab group had reached that 90% improvement mark. Similarly, the percentage of participants whose skin was rated "clear" or "almost clear" by a clinician rose over the 26-week period — reaching 60.0% for abrocitinib and 50.8% for dupilumab by week 26, according to the reported figures. The reported data also shows that for a slightly lower threshold — a 75% or greater improvement in eczema area and severity — 76.1% of the abrocitinib group and 71.1% of the dupilumab group met that level by week 26. These are summary numbers from the trial as a whole; the data submitted did not break results down by individual characteristics such as age or disease history. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 42365219) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Eczema Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years of age or older
- You have been diagnosed with long-term (chronic) atopic dermatitis (eczema) for at least 6 months
- Your eczema is considered moderate to severe, based on scores measured by your doctor across several standard rating scales (confirm with trial site)
- Your eczema has not responded well enough to medicated creams or ointments, or you have needed oral/injectable medications to manage it
Who may not be able to join:
- You have a serious ongoing or sudden medical condition, or abnormal lab results, that could make participation risky
- You have a higher-than-normal risk of developing blood clots in your veins
- You are unwilling or unable to stop your current eczema medications before or during the study, or you need to take medications that are not allowed in the trial
- You have previously been treated with certain specific types of medications for eczema, including JAK inhibitors or biologics such as dupilumab (Dupixent), lebrikizumab, or tralokinumab
- You have another active skin condition or inflammatory skin disease other than eczema
- You have a medical history that includes blood-related disorders, certain cancers, certain infections, or other serious conditions (confirm with trial site for full details)
- You are pregnant, breastfeeding, or able to become pregnant but unwilling to use contraception during the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pfizer CT.gov Call Center, Pfizer
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
8 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants Achieving Greater Than or Equal to (>=) 4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) From Baseline at Week 2; Percentage of Participants Achieving >= 90% Improvement From Baseline in Eczema Area and Severity Index (EASI-90) Response at Week 4
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.